Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: A single-institution experience

Transplant Infectious Disease

Volumn 12, Issue 4, 2010, Pages 316-321

  Zhang, P ^a,b   Jiang, E L ^a   Yang, D L ^a   Yan, Z S ^a   Huang, Y ^a   Wei, J L ^a   Wang, M ^a   Ma, Q L ^a   Liu, Q G ^a   Zou, D H ^a   He, Y ^a   Qiu, L G ^a   Feng, S Z ^a   Han, M Z ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

hematopoietic stem cell transplantation; invasive fungal infections; prognosis; risk factors; risk stratification

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS; CANDIDA; CHILD; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; SYSTEMIC MYCOSIS;

ADOLESCENT; ADULT; ASPERGILLOSIS; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYCOSES; PROGNOSIS; RISK FACTORS; STEROIDS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77955972757     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00497.x     Document Type: Article

References (26)

1. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 34 : 909 917.
2. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008 47 (8) : 1041 1050.
3. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006 91 (8) : 1068 1075.
4. O'Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003 438 472.
5. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006 91 : 986 989.
6. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007 44 : 531 540.
7. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005 106 (8) : 2641 2645.
8. Ribaud P, Chastang C, Latgé JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999 28 : 322 330.
9. Labbé AC, Su SH, Laverdière M, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007 13 (10) : 1192 1200.
10. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003 102 (3) : 827 833.
11. Martino R, Subirá M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002 116 : 475 482.
12. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006 42 (7) : 955 963.
13. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 (4) : 335 347.
14. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004 103 (4) : 1527 1533.
15. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003 138 (9) : 705 713.
16. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007 25 (34) : 5471 5489.
17. Hachem R, Sumoza D, Hanna H, Girgawy E, Munsell M, Raad I. Clinical and radiologic predictors of invasive pulmonary aspergillosis in cancer patients: should the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria be revised? Cancer 2006 106 (7) : 1581 1586.
18. Grigg AP, Brown M, Roberts AW, Szer J, Slavin MA. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Bone Marrow Transplant 2004 34 (5) : 447 453.
19. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008 46 (12) : 1813 1821.
20. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974 18 (4) : 295 304.
21. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001 28 (10) : 909 901.
22. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001 28 (11) : 1001 1011.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risks. J Am Statist Assoc 1999 94 : 496 509.
24. R Development Core Team. R: A language and environment for statistical computing. ISBN 3-900051-07-0. Vienna, Austria : R Foundation for Statistical Computing, 2008. Available at.
25. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007 9 (3) : 189 195.
26. Moreno JM, Alhambra A, Cuétara MS, et al. Incidence of invasive fungal infection in adult haematological malignancy: a prospective validation of a risk stratification scheme. Br J Haematol 2006 134 (3) : 343 345.